Published in Int J Radiat Oncol Biol Phys on January 01, 2007
Costs and trends in pancreatic cancer treatment. Cancer (2012) 1.04
Health-related quality of life in veterans with prevalent total knee arthroplasty and total hip arthroplasty. Rheumatology (Oxford) (2008) 0.89
Cost-effectiveness of preoperative biliary drainage for obstructive jaundice in pancreatic and periampullary cancer. J Surg Res (2014) 0.81
Cost-effectiveness of diagnostic laparoscopy for assessing resectability in pancreatic and periampullary cancer. BMC Gastroenterol (2015) 0.79
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med (2002) 7.00
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 6.99
Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med (2007) 6.98
Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med (2009) 6.46
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol (2009) 4.39
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ (2004) 4.13
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Physician factors associated with discussions about end-of-life care. Cancer (2010) 3.54
Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA (2011) 3.41
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33
How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) (2010) 3.24
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst (2010) 3.05
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Estimating the energy gap among US children: a counterfactual approach. Pediatrics (2006) 2.93
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol (2008) 2.68
Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med (2008) 2.64
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Cost-effectiveness of antibiotic prophylaxis for dental patients with prosthetic joints: Comparisons of antibiotic regimens for patients with total hip arthroplasty. J Am Dent Assoc (2015) 2.60
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA (2012) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43
Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev (2012) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr (2010) 2.25
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol (2005) 2.21
Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2010) 2.16
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. Value Health (2012) 2.14
Parents' views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol (2008) 2.12
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst (2003) 2.11
Forecasting the obesity epidemic in the aging U.S. population. Obesity (Silver Spring) (2007) 2.09
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer (2010) 2.01
Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med (2013) 2.00
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Prominent phenotypic variability associated with mutations in Progranulin. Neurobiol Aging (2007) 2.00
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med (2002) 1.90
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Treatment decision making in early-stage breast cancer: should surgeons match patients' desired level of involvement? J Clin Oncol (2002) 1.89
Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol (2007) 1.87
Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst (2012) 1.87
Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol (2010) 1.84
Parent and physician perspectives on quality of care at the end of life in children with cancer. J Clin Oncol (2005) 1.78
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol (2006) 1.75
Racial and ethnic differences in end-of-life care in fee-for-service Medicare beneficiaries with advanced cancer. J Am Geriatr Soc (2008) 1.74
Hope and prognostic disclosure. J Clin Oncol (2007) 1.73
Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol (2007) 1.73
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making (2011) 1.71
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr (2013) 1.71